New Delhi. The work of vaccination of children against Coronavirus can start in the second week of November. According to information received by , the Subject Expert Committee of the Drug Controller General of India (DCGI) has approved Bharat Biotech’s vaccine for Covaxin for immunization of children aged 2 to 18 years. In children’s vaccination campaign, first priority will be given to children suffering from chronic and serious diseases. The list of critical diseases will be prepared in the next three weeks.
The Drug Controller General of India (DCGI) is reviewing the recommendations received in this regard and once these are approved, the vaccination campaign will start from next month. A senior government official, on condition of anonymity, said, “After the vaccine is approved by DCGI, members of the National Technical Advisory Group on Immunization take matters into their own hands and use the data submitted by the company for approval. make an assessment. They can also seek additional inputs from Bharat Biotech.
He said, ‘Based on the data related to the efficacy and safety of the vaccine, NTAGI will prepare a priority list for children in vaccination. It may take three weeks to prepare the list. This list will be the backbone of the children’s immunization campaign and will help in making concrete plans.
NTAGI member source said that there is a need to understand how many doses Bharat Biotech can provide at the beginning of the vaccination campaign and how many doses will be available in the next three months. He said that once the right balance is struck in the supply of covaccine for adults and children, vaccination of children can start in mid-November or in the second fortnight. The source said that their main concern is not to allow any disruption in the vaccination of adults due to vaccination of children.
Let us tell you that Covaccine is the second vaccine in the country, which has been approved for the vaccination of children in India. Earlier, Zydus Healthcare’s vaccine Zycov-D has been approved by the government for immunization of children above 12 years. However, Covaccine is the first vaccine approved to vaccinate children aged 2 to 18 years around the world. The company will have to submit its data every 15 days.
Two doses of Covaccine will be given at an interval of 28 days. Children will be given a 0.5ml dose of the vaccine, as is given to adults. The subject expert committee of DCGI has asked the company to continue its study under the protocol. The panel has also asked the company to submit safety data, including data related to adverse effects or side effects of people due to the vaccine. This data will have to be submitted every 15 days for the first 2 months. After that it will be submitted every month.
Let us tell you that even when the panel had approved the covaccine for adults, similar conditions were placed before Bharat Biotech. Bharat Biotech on Tuesday said it has submitted clinical data on children aged 2 to 18 to the Central Drugs Standard Control Organization (CDSCO). Bharat Biotech said that this is the first vaccine to be approved for the vaccination of children aged 2 to 18 years globally. We now await further regulatory approval from CDSCO before the launch of the product and availability of Covaccine for children in the market.
Read Hindi News Online Watch More Live TV on Hindi website. Know related to country and abroad and your state, Bollywood, sports world, business News in Hindi.